International Programs Face Significant Challenges Reducing the Supply of Illegal Drugs but Support Broad U.S. Foreign Policy Objectives

July 2010
GAO Reports;7/21/2010, preceding p1
Government Documents
The article presents a speech by Jesse T. Ford, director of International Affairs and Trade, at the Subcommittee on Domestic Policy, Committee on Oversight and Government Reform, U.S. House of Representatives, in which he discussed the significant challenges by the International programs in reducing the supply of illegal drugs.


Related Articles

  • The United States Needs Better Performance Measures for Its Counternarcotics and Anticrime Support Efforts.  // GAO Reports;7/21/2010, preceding p1 

    The article presents a speech by Jess T. Ford, director of the International Affairs and Trade team, at the Subcommittee on the Western Hemisphere, Committee on Foreign Affairs, U.S. House of Representatives, in which he discussed the need of the country to have better performance measures for...

  • House Approves Drug Cost Measure.  // Chemical Market Reporter;06/26/2000, Vol. 257 Issue 26, p7 

    Reports that the United States (U.S.) House of Representatives has approved an amendment that would require the U.S. National Institutes of Health to order pharmaceutical companies to sell drugs developed with federal funds at reasonable prices. Chief sponsor of the U.S. Health and Human...

  • House to follow Senate on FDA reform push. Hess, Glenn // Chemical Market Reporter;07/28/97, Vol. 252 Issue 4, p19 

    Reports on the efforts of the House Commerce Committee to draft a bill similar to the Senate legislation aimed at reforming the Food and Drug Administration's drug approval process and renewal of user fee program of the pharmaceutical industry. Legislators involved in the drafting of the bill.

  • House Considers Drug Patent Legislation.  // Chemical Market Reporter;05/31/99, Vol. 255 Issue 22, p6 

    Details the legislation introduced in the United States House that could extend the patents for several pharmaceutical products. Patents for Schering-Plough's allergy drug, Claritin; Sponsor of the bill; Opposition of the generic drug industry to the bill.

  • Sparks fly from new exclusivity proposal. Dickinson, James G. // Medical Marketing & Media;Jul98, Vol. 33 Issue 7, p32 

    Reports on the reaction of the United States House Judiciary courts to the proposal to abolish congressional action on individual drug patent-extension bills, and have the Patent Office deal with such matters. Arguments made by Representative Henry Waxman on the Waxman-Hatch Act; Identification...

  • Hill debate on drug benefit initiates salvos on overall Medicare reform. Hansen, Dave // AHA News;02/21/2000, Vol. 36 Issue 7, p1 

    Reports that the United States House disagreed on whether a prescription drug benefit should be linked with overall Medicare reform. Complain of hospitals on drug costs; Views on the effect of prescription drug benefit to Medicare spending.

  • Track & Trace Bill Advances.  // BioWorld Today;5/17/2013, Vol. 24 Issue 95, p10 

    The article reports on the decision of the U.S. Energy and Commerce Committee to send the drug track-and-trace bill to the U.S. House of Representatives in May 2013.

  • Medicare Changes Debated in House. Serafini, Marilyn Werber; Smallen, Jill // National Journal;1/13/2007, Vol. 39 Issue 2, p49 

    The article reports on the possibility that the U.S. House of Representatives will pass legislation on January 12, 2007 requiring the Health and Human Services secretary to negotiate directly with pharmaceutical companies for lower prices on medicines covered under Medicare's prescription drug...

  • Feds Propose Drug Reinsurance. Bell, Allison // National Underwriter / Life & Health Financial Services;8/21/2000, Vol. 104 Issue 34, p7 

    Reports on the plan of the United States Congress to propose a government-run drug reinsurance program for elderly and disabled people. Information on the Medicare prescription drug bill passed by the House of Representatives; Percentage of Medicare recipients who are without drug coverage;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics